Tianci International, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 19th, 2025 • Tianci International, Inc. • Computer communications equipment • New York
Contract Type FiledFebruary 19th, 2025 Company Industry Jurisdiction
SOCIETY PASS INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2022 • Society Pass Incorporated. • Services-business services, nec • New York
Contract Type FiledFebruary 14th, 2022 Company Industry JurisdictionThe undersigned, Society Pass Incorporated, a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A)(i) an aggregate of 3,030,300 shares of common stock, (the “Firm Shares”) par value $0.0001 per share of the Company (“Common Stock”) and (ii) an aggregate of 3,030,300 common stock purchase warrants (“Firm Warrants”) and (B) at the election of the Representative,(i) up to an additional 454,545 shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares”) and/or (ii) up to an additional 454,545 common stock purchase warrants (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”).The shares of Common Stock issuable upon the exercise of the
SOCIETY PASS INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • January 14th, 2022 • Society Pass Incorporated. • Services-business services, nec • New York
Contract Type FiledJanuary 14th, 2022 Company Industry JurisdictionThe undersigned, Society Pass Incorporated, a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A)(i) an aggregate of ____________ shares of common stock, (the “Firm Shares”) par value $0.0001 per share of the Company (“Common Stock”) and (ii) an aggregate of [●] common stock purchase warrants (“Firm Warrants”) and (B) at the election of the Representative,(i) up to an additional _________ shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares”) and/or (ii) up to an additional ________ common stock purchase warrants (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”).The shares of Common Stock issuable upon the exercise of the
SIYATA MOBILE INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 28th, 2021 • Siyata Mobile Inc. • Radiotelephone communications • New York
Contract Type FiledDecember 28th, 2021 Company Industry JurisdictionThe undersigned, Siyata Mobile Inc., a corporation incorporated under the laws of British Columbia (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A) an aggregate of [_______] units, (the “Units”), each unit consisting of one common share, no par value per share of the Company (“Common Shares” and the Common Shares sold as part of the Units, the (“Firm Shares”)) together with a warrant to purchase one Common Share (the “Warrant”) at an exercise price of $[___] per share (the warrants sold as part of the Units, the “Firm Warrants”), (B) an aggregate of [_____] pre-funded units (the “Pre-Funded Units”), each Pre-Funded Unit consisting of one pre-funded warrant to purchase one Common Share (the “Pre-Funded Warrant
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Units Consisting of [*] Shares of Common Stock And [*] Warrants to Purchase [*] Shares of Common StockUnderwriting Agreement • November 16th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 16th, 2020 Company Industry JurisdictionLIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [__] Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The [__] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreeme
COPSYNC, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 18th, 2015 • COPsync, Inc. • Computer communications equipment • New York
Contract Type FiledNovember 18th, 2015 Company Industry JurisdictionThe undersigned, COPsync, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim”) and Aegis Capital Corp. are acting as representatives (in such capacity, the “Representatives”), the “Underwriters” and each an “Underwriter”) to issue and sell to the Underwriters an aggregate of 3,028,572 Shares (“Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”), together with warrants to purchase an aggregate of 3,028,572 shares of Common Stock at an exercise price equal to $3.125 per share (each a “Warrant” and collectively, the “Warrants”). The offering and sale of securities contemplated by this Agreement is referred to herein as the “Offering.”
CAPNIA, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • November 4th, 2014 • Capnia, Inc. • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledNovember 4th, 2014 Company Industry JurisdictionThe undersigned, Capnia, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of units (the “Firm Units”) of the Company’s securities, and, at the election of the Representative, up to all of the Option Shares (as defined below), Option Series A Warrants (as defined below), and Option Series B Warrants (as defined below and collectively with the Option Shares and the Option Series A Warrants, (the “Option Units”) of the Company’s securities (the Firm Units and the Option Units that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Units”). Each Unit consists of one share of the Company’s common stock, par value $0.001 per shar